SEARCH

SEARCH BY CITATION

Keywords:

  • chemotherapy, adjuvant/adverse effects;
  • breast neoplasms;
  • cognition disorders;
  • menopause, premature;
  • psychology, medical

Abstract

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. Acknowledgements
  7. REFERENCES

BACKGROUND.

It is believed widely that chemotherapy-induced cognitive impairment occurs in a subgroup of patients with breast cancer. However, recent reports have provided no evidence that chemotherapy affects cognition. In this study, the authors questioned whether cognitive compromise in patients with breast cancer is attributable to chemotherapy. In addition, the effects of therapy-induced menopause and of the erythropoiesis-stimulating factor darbepoetin α on cognitive performance were assessed.

METHODS.

A battery of neuropsychological tests was used to assess cognitive performance in 101 patients with breast cancer before neoadjuvant chemotherapy (T1) and toward the end of neoadjuvant chemotherapy (T2) with combined epirubicin, paclitaxel, and cyclophosphamide with concomitant darbepoetin α. Repeated-measures multiple analyses of variance and a reliable-change approach were used for statistical analyses.

RESULTS.

At T1, the group means ranged below the test norms in 5 of 12 cognitive tests. At T2, multiple analyses of variance (MANOVA) indicated a significant overall improvement in the test results (P < .001). After correcting for practice effects, cognitive decline predominated in 27% of patients, whereas improvement predominated in 28% of patients. Cognitive performance was not related significantly to self-reported cognitive problems, anxiety and depression, menopause, or darbepoetin α administration.

CONCLUSIONS.

Even before chemotherapy, a subgroup of patients with breast cancer showed cognitive compromise that was unrelated to anxiety or depression. During chemotherapy, cognitive function remained stable in most patients, improved in a subgroup, and deteriorated in another subgroup. The deterioration may have been caused by side effects of chemotherapy, but it also may have been related to currently unidentified factors that cause prechemotherapy cognitive compromise. Therapy-induced menopause and darbepoetin α did not appear to influence cognition. Cancer 2007. © 2007 American Cancer Society.

Many patients with breast cancer report chemotherapy-associated cognitive compromise. In 1995, in the first of a series of cross-sectional studies with early breast cancer patients, cognitive impairment was observed after cytostatic treatment in 75% of patients.1 Although the results of subsequent cross-sectional trials assessing cognitive function during or after chemotherapy2–7 were less dramatic, all of them reported substantial cognitive impairment rates of 16% to 50%, suggesting detrimental cytostatic side effects on cognitive function in a subgroup of patients with breast cancer. The first 3 reports that were published on longitudinal studies provided further support for this hypothesis.8–10 Thus, the existence of chemo brain has become almost universally accepted,11 although many details of the concept are controversial or obscure. The reported rates of cognitively impaired patients vary widely, reflecting different definitions of impairment.11 Data regarding affected cognitive domains and the duration of cognitive disturbance are far from being congruent.5, 12, 13 It remains unknown which cytostatic agents are responsible for cognitive impairment, which characteristics make patients vulnerable,14 and which biologic mechanisms are involved.15

Some doubts regarding the evidence for chemotherapy-induced cognitive impairment have been raised by 3 recently published studies that failed to confirm the adverse effects of chemotherapy on cognitive function.16–18 Meta-analyses also consistently have stated that it depends on the study design whether chemotherapy-related cognitive impairment is observed, with more appropriate designs resulting in less clear evidence or no evidence of chemotherapy-induced cognitive impairment.19–21

Currently, we are conducting a multicenter, prospective study entitled Cognitive Impairment in Therapy of Breast Cancer (COGITO). Cognitive function in early breast cancer patients is assessed before the start of neoadjuvant chemotherapy, toward the end of chemotherapy, and 1 year after the baseline assessment. The study is ongoing; this report describes the findings from the first 2 assessments.

The objective of the study was to assess the course of cognitive function before and after exposure to cytostatic treatment and, thus, to test the hypothesis that the cognitive dysfunction observed in patients with breast cancer is induced by chemotherapy. Our secondary objectives were to determine the impact of therapy-induced menopause and the effect of concomitant medication with darbepoetin α on cognition. Darbepoetin α is a hyperglycosylated, human-recombinant erythropoietin, and favorable effects of erythropoietin on cognitive performance during adjuvant chemotherapy have been reported.22

MATERIALS AND METHODS

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. Acknowledgements
  7. REFERENCES

Patients

All patients who had been included in the Preoperative Epirubicin Paclitaxel Aranesp (PREPARE) trial between July 2003 and March 2005 at 5 gynecologic or oncologic centers in Germany were eligible for participation in COGITO if they were fluent in German. Participants in the PREPARE trial are between ages ≥18 years and ≤65 years, have breast carcinomas that measure ≥2 cm or inflammatory lesions, and have no evidence of metastases. In the PREPARE trial, patients are assigned randomly to receive standard chemotherapy (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 on Day 1 every 21 days for 4 cycles; paclitaxel 175 mg/m2 on Day 1 every 21 days for 4 cycles) or dose-intensified therapy (epirubicin 150 mg/m2 on Day 1 every 14 days for 3 cycles; paclitaxel 225 mg/m2 on Day 1 every 14 days for 3 cycles; combined cyclophosphamide, methotrexate, fluorouracil on Days 1 and 8 every 28 days for 3 cycles), and are subrandomized to receive concomitant anemia prophylaxis with darbepoetin α (Aranesp; Amgen Ltd., Munich, Germany) (1 × 4.5 μg/kg every 2 weeks; medication is suspended if hemoglobin exceeds 14 g/dL). Patients who terminated chemotherapy prematurely continued to be included in COGITO if they received ≥4 cycles of chemotherapy.

For the sake of representativeness, we did not establish rigid exclusion criteria. Instead, we performed analyses twice—including all patients and including only patients who were not affected by potential confounders. Features that were considered to be confounding factors were daily alcohol intake of >2 drinks, use of medication known to affect cognition, and a history of a central nervous system disorder. The nonnative speakers who participate in the study, although they are fluent in German, still may be handicapped slightly on the language-related tests; thus, not being a native speaker of German also was regarded as a confounder.

Written informed consent was provided by all patients. The study was approved by the ethics committees at all of the universities involved.

Assessments

The first assessment (T1; baseline) was conducted before the start of preoperative chemotherapy and 1 week after diagnosis at the earliest. The second assessment (T2) was scheduled between the penultimate and the final chemotherapy session—ie, approximately 5 months after the baseline assessment.

A battery of cognitive tests was compiled that was sensitive for detecting dysfunction in a wide range of cognitive domains. Twelve standardized and widely used tests were included: Logical Memory I and II (verbal memory) from the Wechsler Memory Scale-Revised (WMS-R),23 Digit Span Forward (verbal short-term memory, attention) and Digit Span Backward (verbal working memory) from the WMS-R, Digit Symbol (psychomotor function, information processing speed) from the Wechsler Adult Intelligence Scale-Revised (WAIS-R),24 the D2 Test25 (concentration), Trail Making Test Part A (TMT-A)26–28 (psychomotor function, selective attention29), Trail Making Test Part B (TMT-B)26–28 (psychomotor function, divided attention, cognitive flexibility29), and the Regensburg Word Fluency Test (RWT)30 with the subtests Lexical Search, Semantic Search, Lexical Search with Change of Category, and Semantic Search with Change of Category (executive function). With the word-fluency tests, parallel forms were used to minimize practice effects.

The MWT-B,31 a validated, language-related test, was used to estimate premorbid intelligence. Testees are required to find correct words among nonsense neologisms. The test was taken once at T2.

Patients' self-reports of cognitive functioning were covered by the Fragebogen erlebter Defizite der Aufmerksamkeit [Questionnaire of Experienced Attention Deficits (FEDA)],32 a validated questionnaire of attention deficits experienced in daily life, and the Cognitive Function Scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-life Questionnaire C30, version 3.0.33, 34 The Hospital Anxiety and Depression Scale (HADS)35 was used to measure current levels of depression and anxiety symptoms.

All of the assessments were conducted by 1 of 2 university-qualified psychologists, either in patients' homes or in a hospital. Tests and questionnaires were administered in a fixed order.

Statistical Analysis

All statistical analyses were carried out using the Statistical Package for the Social Sciences (SPSS), version 13 or 14. Statistical tests were 2-sided. Significance was calculated with a 5% probability of error (except for reliable-change index calculations; see below).

For comparisons with test norms, either 1-sample t tests or binomial tests, as appropriate, were performed. Test norms for TMT-A and TMT-B were taken from a United States normative study.28 For all other tests, we used norms that were representative of the German population.23–25, 30 All norms were stratified for age.

For group comparisons of the T1 and T2 results of cognitive tests, a repeated-measures MANOVA was carried out, thus avoiding inflation of α error by multiple testing. To determine whether differences between an individual patient's T2 and T1 test results were caused by measurement error or reflected a change in cognitive ability, we used the reliable-change index (RCI) developed by Jacobson and Truax.36 Setting the probability of error at 10%, we calculated the RCI for each pair of T1 and T2 test results, using the standard deviation of the T1 test results, and published test-retest reliabilities.23, 24, 27, 37

Practice effects were to be expected for Logical Memory I and II, TMT-A, TMT-B, and Digit Symbol,38, 39 but not for Digit Spans Forward and Backward.23, 39 To correct the RCI for practice effects, we used practice effects observed in healthy control groups in normative studies (Table 1).23, 40, 41 The D2 Test had to be excluded from this analysis because of a lack of data about the practice effects. In addition, the word-fluency tests were excepted from RCI analyses; because, with these tests, parallel forms were applied that could not be compared directly.

Table 1. Corrections of Test Results Toward the End of Neoadjuvant Chemotherapy (T2) for Practice Effects
TestCorrectionBased on sourceGroupTest-retest interval
  • SD indicates standard deviation.

  • *

    Numbers represent points (subtracted from T2 test results).

  • See Harting et al., 2004.23

  • See Youngjohn et al., 1992.40

  • §

    Numbers represent seconds (added from T2 test results).

  • See Bruggemans et al., 1997.41

Logical Memory I−3.15*Test manualNormative sample, representative (age, education) for German population, N = 406 mo
Logical Memory II−4.37*Same as Logical Memory I  
Digit Span ForwardNo correctionSame as Logical Memory I  
Digit Span BackwardNo correctionSame as Logical Memory I  
Digit Symbol−2.88*Study on test-retest reliability of diverse cognitive testsControl group, N = 115 (mean age ± SD, 48.9 ± 19.3 y)21 d
Trail Making Test Part A4.91§Study on test-retest reliability and practice effectsControl group, N = 63 (mean age ± SD, 56.2 ± SD 11.0 y)6 mo
Trail Making Test Part B10.06§Same as Trail Making Test Part A  

Spearman rank correlations were calculated for each patient's number of deteriorated test results corrected for practice effects with self-reported cognitive function, anxiety, and depression. Repeated-measures MANOVAs were performed to assess effects of darbepoetin α and of therapy-induced menopause.

RESULTS

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. Acknowledgements
  7. REFERENCES

The participation criteria were met by 160 patients. Of these, 26 patients (16%) declined to participate. For another 21 patients (13%), it was not possible to arrange an assessment session before the start of therapy. Of 113 patients who were recruited into the study, 4 patients were excluded as screening failures, and 109 patients completed the T1 assessment. At T2, 2 patients declined further participation, and 6 patients had to be excluded because they discontinued chemotherapy before completing the fourth cycle (attrition rate, 7.3%). Four of the remaining 101 patients had received fewer chemotherapy cycles than scheduled.

At T1, 18 patients had potential confounders (see Materials and Methods, above), including alcohol intake in 2 patients, central nervous system disorders in 6 patients, medications in 7 patients, and 3 patients who were nonnative German-language speakers. At T2, another 6 patients had started medications that were considered confounding (mostly antidepressants), and 1 patient had acquired an unclear neurologic problem (symptoms of paralysis).

With regard to premorbid intelligence and educational levels, the sample was in the above-average range (mean intelligence quotient, 108), and 34% had ≥12 years of education (compared with 22% in the general German population matched for age). Table 2 lists the demographic data for the sample.

Table 2. Demographic Characteristics of Patients at T1 (Before Neoadjuvant Chemotherapy)
CharacteristicMean ± SDNo. of patients (%)
  • SD indicates standard deviation.

  • *

    Premorbid IQ was assessed at T2 (toward the end of neoadjuvant chemotherapy).

  • Premenopausal indicates with regular menses; perimenopausal, last menses >6 weeks but <1 year previously; postmenopausal, last menses >1 year previously or age >60, or bilateral oophorectomy.

Age (N = 109), y48.6 ± 9.7 
 <30 3 (2.8)
 30–39 20 (18.3)
 40–49 35 (32.1)
 50–59 35 (32.1)
 >59 16 (14.7)
Years of education (N = 109)
 ≤11 72 (66.1)
 ≥12 37 (33.9)
Premorbid IQ (N = 101)*107.7 ± 14.7 
 71–85 3 (3)
 86–100 36 (35.6)
 101–115 32 (31.7)
 116–130 22 (21.8)
 ≥131 8 (7.9)
Menopausal status (N = 109)
 Premenopausal 52 (47.7)
 Perimenopausal 9 (8.3)
 Postmenopausal 48 (44)

Before the Start of Therapy—T1

The group mean scores for 5 cognitive tests showed significantly poorer scores than the test norms, whereas the group mean score for 1 test was significantly better than the norm (Table 3). If 18 patients with confounders were excluded, then the scores for 4 tests remained significantly poorer than the norms (no longer including the RWT Semantic Search), whereas 3 tests were significantly better (in addition, the Digit Span Forward and the RWT Semantic Search with Change of Category).

Table 3. Results of Cognitive Tests Before (T1) and Toward the End (T2) of Neoadjuvant Chemotherapy
TestMean (SD)Z-score/PR*Compared with test normsPNo.
  • SD indicates standard deviation; PR, percent rank; NS, nonsignificant; RWT, Regensburg Word Fluency Test.

  • *

    For normally distributed results, Z-scores are given; for results that were not distributed normally, percent ranks are given.

  • Z-score relative to test norms.

  • Numbers represent seconds, with smaller numbers signifying better performance.

  • §

    Percent rank relative to test norms.

  • Parallel test forms were used at T1 and T2.

Logical Memory 1
 T128.58 (7.58)0.17NS 109
 T230.51 (6.56)0.47Better<.001101
Logical Memory 2
 T124.06 (8.11)0.04NS 109
 T227.76 (8.04)0.59Better<.001101
Digit Span Forward
 T18.12 (2.08)0.22NS 109
 T28.36 (1.92)0.36Better.001101
Digit Span Backward
 T16.77 (2.23)−0.06NS 109
 T27.25 (2.36)0.19NS 101
Digit Symbol
 T153.86 (12.82)0.95Better<.001108
 T256.07 (14.58)1.12Better<.001100
D2 Test
 T1134.62 (42.30)−0.57Poorer<.001107
 T2150.86 (40.28)−0.18NS 99
Trail Making Test Part A
 T134.02 (13.84)43§NS 108
 T232.00 (12.65)47§NS 100
Trail Making Test Part B
 T179.92 (36.95)37§Poorer.003108
 T278.51 (50.71)44§NS 100
RWT Lexical Search
 T114.86 (5.96)35§Poorer<.001107
 T217.89 (5.35)38§Poorer.001100
RWT Semantic Search
 T134.61 (8.34)43§Poorer.021109
 T235.70 (9.47)50§NS 100
RWT Lexical Search With Change of Category
 T119.81 (5.92)36§Poorer<.001108
 T220.85 (6.49)41§Poorer.017101
RWT Semantic Search With Change of Category
 T123.43 (4.78)56NS 109
 T222.71 (4.54)52NS 101

On an individual level, 33 patients (31%) had ≥2 test results in the lower 5% range, and 29 patients (27%) had ≥2 test results in the upper 5% range (Fig. 1). The percentages changed marginally (30% and 27%, respectively) if patients with confounders were excluded. The number of test results in the lower 5% range was correlated significantly with premorbid intelligence (Spearman ρ = −0.34; P = .001), and education (Spearman ρ = −0.39; P < .001), but not with anxiety, depression, or self-reported cognitive function.

thumbnail image

Figure 1. Before the start of chemotherapy (T1): Test results in the upper and lower 5% range of test norms. Columns represent patients. Red indicates ≥2 test results ≤5% (n = 33 patients; 31%); green, ≥2 test results ≥5% of the test norms (n = 29 patients; 27%). One patient was excluded, because >1 test result was missing.

Download figure to PowerPoint

If the method of determining cognitive impairment used in the frequently cited study by Wieneke and Dienst had been applied,1 then we would have had to classify 61 patients (56%) with at least mild cognitive impairment (>1 test result ≤1 standard deviation [SD]), with 35 patients (32%) demonstrating moderate cognitive impairment (in addition, ≥1 test result ≤2 SD). If patients with confounders present at T1 were excluded, then the percentages changed marginally (31% moderately impaired).

Toward the End of Chemotherapy—T2

The mean interval between the T1 and the T2 assessments was 20.9 weeks (SD, 1.3 weeks). With the exception of 2 tests, the group mean scores were within or above the test norms at T2 (Table 3).

Repeated-measures MANOVA of 93 data sets that were complete for T1 and T2 indicated a significant overall improvement [P < .001; effect size (partial Eta squared) η2p = 0.59]. Improvement reached significance in 6 tests (Table 4). Deterioration was observed in only 1 test (RWT Semantic Search with Change of Category) and reached significance. With that test, and in all RWT subtests, parallel forms were used at T1 and T2 to minimize practice effects.

Table 4. Repeated-Measures Multiple Analyses of Variance of Test Results Before (T1) and Toward the End (T2) of Neoadjuvant Chemotherapy (N = 93)*
TestFPηmath image(effect size)
  • RWT indicates Regensburg Word Fluency Test.

  • *

    Including patients with complete T1 and T2 data sets. Results are not corrected for practice effects.

  • Significantly improved at T2.

  • Significantly deteriorated at T2.ηmath image indicates effect size (partial Eta squared).

Logical Memory 15.772.018.059
Logical Memory 225.656.000.218
Digit Span Forward0.718.399.008
Digit Span Backward4.255.042.044
Digit Symbol11.833.001.114
D2 Test75.310.000.450
Trail Making Test Part A2.840.095.030
Trail Making Test Part B2.156.145.023
RWT Lexical Search0.720.398.008
RWT Semantic Search6.506.012.066
RWT Lexical Search with Change of Category3.908.051.041
RWT Semantic Search with Change of Category6.075.016.062

If patients who had confounders were excluded, the overall improvement was more pronounced (P < .001; ηmath image = 0.75). There was no consistent pattern of affected cognitive domains. The only overall deterioration was observed in 1 of 4 word-fluency tests. However, the other word-fluency tests showed either improvement or no change.

Forty-eight patients received standard chemotherapy, and 53 patients received dose-intensified chemotherapy. The results from MANOVA showed no effects associated with the treatment arm (interaction time*treatment arm: P = .64).

In the individual RCI analyses, 100 patients with ≤1 missing test result were included. Deterioration predominated in a subset of 27 patients (27%), whereas improvement predominated in 28 patients (28%) (Fig. 2). Excluding 24 patients who had confounders at T1, at T2, or at both T1 and T2 resulted in a lower percentage of predominant deterioration (22%) and a higher percentage of predominant improvement (32%).

thumbnail image

Figure 2. Significantly improved and deteriorated test results from 7 cognitive tests toward the end of neoadjuvant chemotherapy (T2) corrected for practice effects. Columns represent patients. Red indicates deterioration predominant (n = 27 patients; 27%); blue, no change or equal numbers of deteriorated and improved results (n = 45 patients; 45%); green, improvement predominant (n = 28 patients; 28%). One patient was excluded, because >1 test result was missing.

Download figure to PowerPoint

Neither declines nor improvements were related significantly to the number of test results in the lower 5% range at T1. However, the number of test results in the upper 5% range at T1 was correlated positively with declines and negatively with further improvements; ie, patients who had performed particularly well at T1 were more likely to show decline and were unlikely to improve their performance further. Age and intelligence were not associated significantly with the number of deteriorated and improved test results.

A subgroup of 5 patients (5%) showed deterioration on 3 tests (n = 4 patients) or 4 tests (n = 1 patient). Three of those patients were using antidepressant medications at T2. The remaining 2 patients had performed very well at T1 and still performed well at T2 (3 and 2 test results in the upper 5% range, respectively; no test results in the lower 5% range), suggesting regression to the mean.

Both measures of subjective cognitive function showed a significant increase in cognitive problems at T2 (FEDA: P < .001; EORTC Cognitive Function Scale: P < .001). Correlations with the number of deteriorated test results were small and nonsignificant (FEDA: Spearman ρ = −0.13; P = .20; EORTC-Cognitive Function Scale: Spearman ρ = 0.11; P = .30). In addition, changes in self-reported cognitive problems were not associated significantly with the number of deteriorated test results.

Anxiety and depression were not correlated significantly with the number of deteriorated or improved test results, whereas all correlations of anxiety and depression with self-reported cognitive complaints were significant and of moderate size (eg, HADS-A and FEDA: Spearman ρ = 0.41; P < .001; HADS-D and FEDA: Spearman ρ = 0.58; P < .001).

Impact of Therapy-induced Menopause and Darbepoetin α

Among 52 patients who were premenopausal at T1, 3 still were premenopausal at T2, menses had ceased in 45 patients, the menopausal status of 1 patient was indeterminable, and 3 patients had terminated participation in the study. MANOVA with age and intelligence as covariates did not identify any significant effect of therapy-induced menopause (interaction time*induced menopause: P = .29; ηmath image = 0.16).

There were no differences between patients who received (n = 51 patients) or did not receive (n = 50 patients) concomitant darbepoetin α therapy with regard to age, intelligence, or education. MANOVA did not identify any significant influence of darbepoetin α on changes in cognitive performance (interaction of time*darbepoetin α: P = .78; ηmath image = 0.09).

DISCUSSION

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. Acknowledgements
  7. REFERENCES

Even before the start of chemotherapy, the performances of the patients—who had above-average educational and intelligence levels—ranged below the test norms on 5 of 12 tests. Approximately one-third of patients showed cognitive compromise even before treatment. This impairment rate is similar to that reported after chemotherapy in cross-sectional studies. Prechemotherapy cognitive compromise has also been observed in other studies.8, 42, 43

Toward the completion of chemotherapy, approximately a quarter of patients showed a decline, whereas another quarter demonstrated improvement of cognitive function. Practice effects were taken into account. There was no consistent pattern of affected cognitive domains.

Very few patients exhibited a pronounced cognitive decline. All of them were either taking antidepressant medication known to affect cognitive function or had performed extraordinarily well at T1 and still had above-average performance at T2, which may be interpreted as a regression to the mean.

The patients' reports of cognitive problems increased during chemotherapy, and those problems were not related significantly to cognitive test results but, rather, to anxiety and depression. This observation is in accordance with the findings of virtually all studies that have reported on the relations between cognitive performance and cognitive complaints.3, 5, 7, 18, 44 Neither chemotherapy-induced menopause nor concomitant darbepoetin α administration had a significant influence on cognitive change.

The current study was limited by the absence of a control group. Test norms were used to rate the baseline test results, and cognitive performances during chemotherapy were compared only with the patients' own baseline performance. Practice effects were estimated by using effects observed in normative samples that were matched imperfectly to our patient group. One advantage of this study was the homogeneity of treatment. In addition, the attrition rate was very low, and we controlled for confounding factors—even those that emerged after the start of study participation, such as psychoactive medication that commenced during chemotherapy.

Our findings cast some additional doubt on the evidence for chemotherapy-induced cognitive impairment. In cross-sectional studies that used test norms1 or control groups consisting of healthy participants,4, 6, 13 cognitive compromise in the patients may have originated before chemotherapy, like it did in the current study. However, several cross-sectional studies have used control groups consisting of patients with breast cancer who were treated without chemotherapy. The results were mixed: Poorer performances were reported among patients who received chemotherapy,2, 3, 5, 7 although others reported no differences16, 17; the latter findings also were supported by a meta-analysis.21

Two longitudinal studies that provided evidence of chemotherapy effects on cognitive function were limited by their rather small sample sizes (Wefel et al.: N = 18 patients; Bender et al.: N = 36 patients at the T2 assessment). A recently published, large-scale, longitudinal trial by Jenkins et al.18 did not identify any significant differences in cognitive changes between chemotherapy patients, nonchemotherapy patients, and healthy control individuals. The patients were heterogeneous with regard to the chemotherapy regimens administered, with most patients having received only relatively low-dose combined 5-fluorouracil, epirubicin, and cyclophosphamide treatment. The authors considered the regimen a possible reason why cognitive impairment did not become apparent. However, in the current study, all of our patients received quite high doses of chemotherapy that contained anthracycline and taxane, and the rate of decline during chemotherapy still did not exceed the rate of simultaneous improvement.

In contrast to Jenkins et al., we observed cognitive compromise before the start of chemotherapy. This discrepancy between the findings may have been caused by differences in the assessment points: Whereas the baseline assessment took place several weeks after surgery (mean, 41 days) in the study by Jenkins et al., we already had assessed cognitive function after diagnosis—ie, at a time that is known as especially stressful. Cognitive compromise at this particular time may indicate that the still unidentified factor affecting cognitive function before chemotherapy is related to stress-response symptoms. Without necessarily coinciding with symptoms of depression, stress-response symptoms may interfere with performance during cognitive testing.

Conceivably, persistent stress-response symptoms also may have caused the cognitive compromise that we observed during and after chemotherapy in several studies. Posttraumatic symptoms have been identified in subgroups of breast cancer patients even long after the completion of treatment.45 There is some evidence that posttraumatic stress disorder may be associated with memory and concentration problems.46 Further research is needed to determine whether the phenomenon of cognitive compromise associated with breast cancer is dubbed chemo brain correctly or, instead, should be renamed crisis brain.

The results from this study do not corroborate the hypothesis that chemotherapy is the cause of cognitive dysfunction in patients with breast cancer. The possibility cannot be ruled out that the cognitive deterioration evident in a subgroup of patients during chemotherapy is attributable to the side effects of chemotherapy. However, in the light of the apparent cognitive compromise before chemotherapy and improvements observed in a subgroup of patients during chemotherapy, an alternative explanation seems more plausible—namely, that as yet unidentified factors affect cognition in patients with breast cancer even before chemotherapy and affect it further during chemotherapy in a subgroup of patients, when another subgroup starts to recover.

Acknowledgements

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. Acknowledgements
  7. REFERENCES

We are grateful to Franziska Neufeld for conducting many of the assessments, and to the patients, physicians, and research nurses who participated in the Cognitive Impairment in Therapy of Breast Cancer study.

REFERENCES

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. Acknowledgements
  7. REFERENCES
  • 1
    Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology. 1995; 4: 6166.
  • 2
    van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998; 90: 210218.
  • 3
    Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999; 85: 640650.
  • 4
    Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000; 18: 26952701.
  • 5
    Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002; 20: 485493.
  • 6
    Tchen N, Juffs HG, Downie FP, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol. 2003; 21: 41754183.
  • 7
    Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004; 26: 955969.
  • 8
    Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004; 100: 22922299.
  • 9
    Shilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D. The effects of adjuvant chemotherapy on cognition in women with breast cancer—preliminary results of an observational longitudinal study. Breast. 2005; 14: 142150.
  • 10
    Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2006; 15: 422430.
  • 11
    Shilling V, Jenkins V, Trapala IS. The (mis)classification of chemo-fog—methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat. 2006; 95: 125129.
  • 12
    Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002; 13: 13871397.
  • 13
    Fan HG, Houede-Tchen N, Yi QL, et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol. 2005; 23: 80258032.
  • 14
    Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003; 12: 612619.
  • 15
    Ahles TA, Saykin A. Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest. 2001; 19: 812820.
  • 16
    Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer. 2005; 104: 24992507.
  • 17
    Scherwath A, Mehnert A, Schleimer B, et al. Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol. 2006; 17: 415423.
  • 18
    Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006; 94: 828834.
  • 19
    Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc. 2003; 9: 967982.
  • 20
    Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005; 59: 6070.
  • 21
    Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer. 2005; 104: 22222233.
  • 22
    O'Shaughnessy JA, Vukelja SJ, Holmes FA, et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer. 2005; 5: 439446.
  • 23
    Harting C, Markowitsch HJ, Neufeld H, Calabrese P, Deisinger K, Kessler J. WMS-R. Wechsler Gedachtnistest-Revidierte Fassung [in German]. 2nd ed. Bern: Huber, 2004.
  • 24
    Tewes U. HAWIE-R. Hamburg-Wechsler Intelligen Test for Erwachsene, revision 1991, 2nd ed [in German]. Bern: Huber; 1994.
  • 25
    Brickenkamp R. Test D2. Aufmerksamkeits-Belastungs-Test, 9th ed [in German]. Gottingen: Hogrefe; 2002.
  • 26
    Reitan RM. Trail Making Test. ed. 2. Tucson, Ariz: Reitan Neuropsychology Laboratory; 1992.
  • 27
    Giovagnoli AR, Del Pesce M, Mascheroni S, Simoncelli M, Laiacona M, Capitani E. Trail Making Test: normative values from 287 normal adult controls. Ital J Neurol Sci. 1996; 17: 305309.
  • 28
    Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004; 19: 203214.
  • 29
    Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. 4th ed. New York, NY: Oxford University Press; 2004.
  • 30
    Aschenbrenner S, Tucha O, Lange KW. RWT. Regensburger Wortflussigkeits-Test [in German]. Gottingen: Hogrefe; 2000.
  • 31
    Lehrl S. Mehrfachwahl-Wortschatz-Intelligenztest MWT-B. Balingen: Spitta; 1999.
  • 32
    Suslow T, Arolt V, Junghanns K. Differentielle Validitat des Fragebogen erlebter Defizite der Aufmerksamkeit (FEDA): konkurrente Validierungsergebnisse bei schizophrenen und depressiven Patienten [in German]. Z Klin Psychol Psychiatr Psychother. 1998; 46: 152165.
  • 33
    Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365376.
  • 34
    Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organization for Research and Treatment of Cancer; 2001.
  • 35
    Herrmann C, Buss U, Snaith RP HADS-D. Hospital Anxiety and Depression Scale. German Version, 1st ed. Berne: Huber; 1995.
  • 36
    Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991; 59: 1219.
  • 37
    De Monte VE, Geffen GM, Kwapil K. Test-retest reliability and practice effects of a rapid screen of mild traumatic brain injury. J Clin Exp Neuropsychol. 2005; 27: 624632.
  • 38
    McCaffrey RJ, Duff K, Westervelt HJ. Practitioner's Guide to Evaluating Change With Neuropsychological Assessment Instruments. New York, NY: Kluwer Academic/Plenum Publishers; 2000.
  • 39
    McCaffrey RJ, Duff K, Westervelt HJ. Practitioner's Guide to Evaluating Change With Intellectual Assessment Instruments. New York, NY: Kluwer Academic/Plenum Publishers; 2000.
  • 40
    Youngjohn JR, Larrabee GJ, Crook TH. Test-retest reliability of computerized, everyday memory measures and traditional memory tests. Clin Neuropsychol. 1992; 6: 276286.
  • 41
    Bruggemans EF, Van de Vijver FJ, Huysmans HA. Assessment of cognitive deterioration in individual patients following cardiac surgery: correcting for measurement error and practice effects. J Clin Exp Neuropsychol. 1997; 19: 543559.
  • 42
    Cimprich B, So H, Ronis DL, Trask C. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psychooncology. 2005; 14: 7078.
  • 43
    Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. “Chemobrain” in breast carcinoma? A prologue. Cancer. 2004; 101: 466475.
  • 44
    Cull A, Hay C, Love SB, Mackie M, Smets E, Stewart M. What do cancer patients mean when they complain of concentration and memory problems? Br J Cancer. 1996; 74: 16741679.
  • 45
    Gurevich M, Devins GM, Rodin GM. Stress response syndromes and cancer: conceptual and assessment issues. Psychosomatics. 2002; 43: 259281.
  • 46
    Horner MD, Hamner MB. Neurocognitive functioning in posttraumatic stress disorder. Neuropsychol Rev. 2002; 12: 1530.